+44 (0) 1223 755950
+1 832 327 7413
Human Kazal Type Serine Protease Inhibitor Domain Containing Protein 1 (KAZALD1) Protein
REQUEST MORE INFO
Catalogue No: abx166238
Price:
US$261.00
(Size: 10 µg)
Reviews: 
(0 Publications and Reviews)
(0 Publications and Reviews)
Click on the image to see the image legend
Human Kazal Type Serine Protease Inhibitor Domain Containing Protein 1 is a recombinant Human protein expressed in E. coli.
Research Articles on Kazal Type Serine Protease Inhibitor Domain Containing Protein 1 (KAZALD1)
| Target | Kazal Type Serine Protease Inhibitor Domain Containing Protein 1 (KAZALD1) |
| Origin | Human |
| Expression | Recombinant |
| Tested Applications | WB, SDS-PAGE |
| Host | E. coli |
| Conjugation | Unconjugated |
| Form | Lyophilized |
| Purity | > 90% |
| Reconstitution | To keep the original salt concentration, we recommend reconstituting to the original concentration prior to lyophilization (see Concentration) in ddH2O. If a lower concentration is required, dilute in 10 mM PBS, pH 7.4. If a higher concentration is required, the product can be reconstituted directly in 10 mM PBS, pH 7.4, though please note that this will change the overall salt concentration. The stock concentration should be between 0.1-1.0 mg/ml. Do not vortex. |
| Storage | Store at 2-8 °C for up to one month. Store at -80 °C for up to one year. Avoid repeated freeze/thaw cycles. |
| UniProt Primary AC | Q96I82 (UniProt, ExPASy) |
| UniProt Secondary AC | D3DR74, Q6ZMB1, Q9BQ73 |
| UniProt Entry Name | KAZD1_HUMAN |
| Gene Symbol | KAZALD1 |
| GeneID | 81621 |
| OMIM | 609208 |
| HGNC | 25460 |
| KEGG | hsa:81621 |
| Ensembl | ENSG00000107821 |
| String | 9606.ENSP00000359219 |
| Molecular Weight | Calculated MW: 33.7 kDa Observed MW (SDS-PAGE): 37 kDa Possible reasons why the actual band size differs from the predicted band size: 1. Splice variants. Alternative splicing may create different sized proteins from the same gene. 2. Relative charge. The composition of amino acids may affect the charge of the protein. 3. Post-translational modification. Phosphorylation, glycoslyation, methylation etc. may affect the band size. 4. Post-translational cleavage. Many proteins are synthesised as pro-proteins, and then cleaved to give the active form. 5. Polymerisation of the target protein. Dimerisation, multimerisation etc. will increase the band size observed. |
| Sequence Fragment | Arg31-Tyr304 |
| Sequence | RPSPGPDYLR RGWMRLLAEG EGCAPCRPEE CAAPRGCLAG RVRDACGCCW ECANLEGQLC DLDPSAHFYG HCGEQLECRL DTGGDLSRGE VPEPLCACRS QSPLCGSDGH TYSQICRLQE AARARPDANL TVAHPGPCES GPQIVSHPYD TWNVTGQDVI FGCEVFAYPM ASIEWRKDGL DIQLPGDDPH ISVQFRGGPQ RFEVTGWLQI QAVRPSDEGT YRCLGRNALG QVEAPASLTV LTPDQLNSTG IPQLRSLNLV PEEEAESEEN DDYY |
| Tag | N-terminal His tag |
| Buffer | Prior to lyophilization: PBS, pH 7.4, containing 0.01% Sarcosyl, 5% Trehalose. |
| Activity | Not tested |
| Concentration | Prior to lyophilization: 500 µg/ml |
| Availability | Shipped within 5-7 working days. |
| Note | This product is for research use only. Not for human consumption, cosmetic, therapeutic or diagnostic use. |